| The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes JW Vardiman, J Thiele, DA Arber, RD Brunning, MJ Borowitz, A Porwit, ... Blood, The Journal of the American Society of Hematology 114 (5), 937-951, 2009 | 6115 | 2009 |
| Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis RL Levine, M Wadleigh, J Cools, BL Ebert, G Wernig, BJP Huntly, ... Cancer cell 7 (4), 387-397, 2005 | 3822 | 2005 |
| A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome J Cools, DJ DeAngelo, J Gotlib, EH Stover, RD Legare, J Cortes, J Kutok, ... New England Journal of Medicine 348 (13), 1201-1214, 2003 | 2153 | 2003 |
| New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment F Cervantes, B Dupriez, A Pereira, F Passamonti, JT Reilly, E Morra, ... Blood, The Journal of the American Society of Hematology 113 (13), 2895-2901, 2009 | 1523 | 2009 |
| Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms A Tefferi, JW Vardiman leukemia 22 (1), 14-22, 2008 | 1511 | 2008 |
| MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients AD Pardanani, RL Levine, T Lasho, Y Pikman, RA Mesa, M Wadleigh, ... Blood 108 (10), 3472-3476, 2006 | 1327 | 2006 |
| Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis S Verstovsek, H Kantarjian, RA Mesa, AD Pardanani, J Cortes-Franco, ... New England Journal of Medicine 363 (12), 1117-1127, 2010 | 1296 | 2010 |
| DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and … N Gangat, D Caramazza, R Vaidya, G George, K Begna, S Schwager, ... Journal of Clinical Oncology 29 (4), 392-397, 2011 | 1214 | 2011 |
| Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis … A Tefferi, J Thiele, A Orazi, HM Kvasnicka, T Barbui, CA Hanson, G Barosi, ... Blood, The Journal of the American Society of Hematology 110 (4), 1092-1097, 2007 | 1179 | 2007 |
| International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data DA Arber, A Orazi, RP Hasserjian, MJ Borowitz, KR Calvo, HM Kvasnicka, ... Blood, The Journal of the American Society of Hematology 140 (11), 1200-1228, 2022 | 1118 | 2022 |
| A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and … F Passamonti, F Cervantes, AM Vannucchi, E Morra, E Rumi, A Pereira, ... Blood, The Journal of the American Society of Hematology 115 (9), 1703-1708, 2010 | 1074 | 2010 |
| Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet T Barbui, G Barosi, G Birgegard, F Cervantes, G Finazzi, M Griesshammer, ... Journal of clinical oncology 29 (6), 761, 2011 | 1029 | 2011 |
| Myelofibrosis with myeloid metaplasia A Tefferi New England Journal of Medicine 342 (17), 1255-1265, 2000 | 934 | 2000 |
| Myelodysplastic syndromes A Tefferi, JW Vardiman New England Journal of Medicine 361 (19), 1872-1885, 2009 | 902 | 2009 |
| Mutations and prognosis in primary myelofibrosis AM Vannucchi, TL Lasho, P Guglielmelli, F Biamonte, A Pardanani, ... Leukemia 27 (9), 1861-1869, 2013 | 868 | 2013 |
| Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis A Tefferi, P Guglielmelli, DR Larson, C Finke, EA Wassie, L Pieri, ... Blood, The Journal of the American Society of Hematology 124 (16), 2507-2513, 2014 | 824 | 2014 |
| Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study A Tefferi, E Rumi, G Finazzi, H Gisslinger, AM Vannucchi, F Rodeghiero, ... Leukemia 27 (9), 1874-1881, 2013 | 813 | 2013 |
| Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders RL Levine, A Pardanani, A Tefferi, DG Gilliland Nature reviews cancer 7 (9), 673-683, 2007 | 741 | 2007 |
| Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 A Tefferi Leukemia 24 (6), 1128-1138, 2010 | 720 | 2010 |
| CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons A Tefferi, TL Lasho, CM Finke, RA Knudson, R Ketterling, CH Hanson, ... Leukemia 28 (7), 1472-1477, 2014 | 688 | 2014 |
